RoyaltiesBioArctic is cashing in on Eisai and Biogen growing sales in Alzheimer’s diseaseStockholm-based BioArctic is receiving SEK 127 million (about €11.9 million at today’s exchange rate) in royalties from the Alzheimer’s disease therapy Leqembi (lecanemab). more ➔
IPOAgomab goes public on Nasdaq as biotech IPOs top $1bn in a single weekJust three weeks after announcing its plans for a U.S. listing, Belgium-based Agomab has gone public on Nasdaq after pricing its IPO at $16 per share, aiming to bring in about $200 million in gross proceeds … more ➔
adobe stock photos - Michael Derrer Fuchs NovartisNovartis celebrates strong profits, while the CEO enjoys record pay triggering discussionNovartis increased its annual profit in 2025 to USD 17.4 billion and raised its dividend. Towards the end of the year, however, growth weakened markedly, weighed down by copycat products. The group has … more ➔
clinical dataLeyden Labs reports first human data for intranasal flu prevention antibodyLeyden Labs has released new early-stage data on its intranasal antibody program for influenza prevention, adding phase 1 human safety results to previously disclosed animal studies. more ➔
chokniti - Adobe StockRadiopharmacyPentixapharm: positive Phase II data on Pentixafor PET diagnostics pave way for radiotherapeuticsPentixapharm Holding AG published new clinical Phase II data on its radiodiagnostic agent [68Ga]Ga-Pentixafor in early February. As the Berlin-based company reported, the results published in the Journal … more ➔
GenomicsPharosAI partners with 10x Genomics on spatial cancer data backed by £18.9 millionPharosAI, a U.K. cancer research consortium bringing together King’s College London, Queen Mary University of London, Guy’s and St Thomas’ National Health Service (NHS) Foundation Trust and Barts … more ➔
Clinical trialsCereno widens clinical program as competition heats up in lung diseaseSwedish biotech Cereno Scientific today announced the expansion of its clinical development program for its investigational small-molecule therapy, CS014, targeting rare lung diseases. more ➔
RestructuringPoxel takes first step in recovery plan with €5 million equity lineFrench biotech Poxel is trying to stabilise its business after judicial reorganisation, with its court-approved recovery plan now moving into the execution phase. The Lyon-based company, which has spent … more ➔
Sartorius AGSartoriusSartorius returns to a path of profitable growth in 2025The Göttingen-based life science group Sartorius AG closed the 2025 financial year, based on preliminary figures, with a marked increase in revenue and earnings. Group sales grew by 7.6% at constant … more ➔
Licence agreementKahimmune launches and secures exclusive license for dark-genome cancer vaccine platformNewly formed French biotech Kahimmune Therapeutics has signed an exclusive licensing agreement with Gustave Roussy and SATT Paris-Saclay, securing rights to a technology platform designed to identify … more ➔
adobe stock photos - Michael Derrer Fuchs 
chokniti - Adobe Stock
Sartorius AG